Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Phase I/IIa Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation Advanced or Recurrent NSCLC

NCT03386955 is registered in ClinicalTrials.gov with Beta Pharma Shanghai as lead sponsor.

NCT NCT03386955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03386955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Phase I/IIa Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation Advanced or Recurrent NSCLC
Lead sponsor
Beta Pharma Shanghai
Phase
Phase 1/2
Overall status
Completed
Start date
August 16, 2017
Completion date
December 23, 2021
Enrollment
215 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer